A new process by which the legal status of medicines is awarded in the UK came into effect on 1 April 2002. Legal status (prescription only, pharmacy or general sale list) is now part of the marketing authorisation rather than determined by the active substance listed in secondary legislation.
This change enables applications to be dealt with faster by removing the need to amend statutory orders. In designing the new reclassification procedures, we took the opportunity to introduce changes to how we consult - some of which were set out in the consultation document MLX 279. Respondents to MLX 279 broadly welcomed the proposed changes to the consultation process. As each application will merit its own consultation, with a dedicated timetable, we will not be using the MLX prefix for reclassification consultations but rather a dedicated prefix - 'ARM' (application to reclassify a medicine).
Contact for further information
For further information on ARMs , please contact the Self-medication Unit, 3.O, 151 Buckingham Palace Road, London SW1W 9SZ or email our Central Enquiry Point.
Latest ARMs
-
06 Feb 2012 | Public consultation (ARM 81): Request to reclassify Imodium Instants (loperamide hydrochloride) 12 tablet pack size from Pharmacy (P) to General Sales List (GSL)
Consultation ARM 81 seeks your views on the reclassification of Imodium Instants (loperamide hydrochloride) 12 tablet pack size from Pharmacy (P) to General Sales List (GSL). Comments are invited by 5 March 2012.
-
12 Jan 2012 | Public consultation (ARM 80): Request to reclassify Clarityn Allergy 10 mg Tablets (Loratadine) 30 tablet pack size from Pharmacy (P) to General Sales List (GSL)
Consultation ARM 80 seeks your views on the reclassification of Clarityn Allergy 10 mg Tablets (Loratadine) 30 tablet pack size from Pharmacy (P) to General Sales List (GSL). The deadline for comments is 8 February 2012.
-
07 Sep 2011 | Public consultation (ARM 79): Request to reclassify Grisol 1% Spray Solution from Pharmacy (P) to General Sales List (GSL)
Consultation ARM 79 seeks your views on the reclassification of Grisol 1% Spray Solution from P to GSL.
-
22 Jul 2011 | Public consultation (ARM 77): Request to reclassify Pariet Pharmacy 10 mg Gastro-Resistant tablet from Prescription Only Medicine (POM) to Pharmacy (P)
Consultation ARM 77 seeks your views on the reclassification of Pariet Pharmacy 10 mg Gastro-Resistant tablet from Prescription Only Medicine (POM) to Pharmacy (P).
-
28 Jun 2011 | Public consultation (ARM 76): Request to reclassify Savlon Cold Sore Cream from Pharmacy (P) to General Sale List (GSL)
Consultation ARM 76 seeks your views on the reclassification of Savlon Cold Sore Cream from Pharmacy (P) to General Sale List (GSL).
-
16 Mar 2011 | Public consultation (ARM 74) - Request to reclassify Crampex tablets from Pharmacy (P) to General Sales List (GSL)
Consultation ARM 74 seeks your views on the reclassification of Crampex Tablets from P to GSL.
-
03 Feb 2011 | Public consultation (ARM 73): Request to reclassify Ibusol lotion from Prescription Only Medicine (POM) to Pharmacy (P)
Consutation ARM 73 seeks your views on the reclassification of Ibusol lotion from Prescription Only Medicine (POM) to Pharmacy (P).
-
10 Jan 2011 | Public consultation (ARM 72): Request to reclassify Bazuka Extra Strength Treatment 26% W/W Gel from pharmacy (P) to General Sale List (GSL)
Consultation ARM 72 sought your views on the reclassification of Bazuka Extra Strength Treatment 26% W/W Gel from Pharmacy (P) to General Sale List (GSL).
-
09 Dec 2010 | Public consultation (ARM 69): Request to reclassify Nicorette 15 mg inhalator from pharmacy (P) to General Sale List (GSL)
Consultation ARM 69 seeks your views on the reclassification of Nicorette 15mg Inhalator from pharmacy (P) to General Sale List (GSL).
-
03 Nov 2010 | Public consultation (ARM 71): Request to reclassify Radian B Ibuprofen 5% w/w Gel 100G from Pharmacy (P) to General Sales List (GSL)
Consultation ARM 71 sought your views on the reclassification from Pharmacy (P) to General Sales List (GSL) of Radian B Ibuprofen 5% w/w Gel.
